Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Almac Secures New Metagenomics and Enzyme Discovery Programme with UCL

Published: Wednesday, May 15, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
The BBRSC Programme combines Chemistry and Biochemical Engineering at UCL with Almac’s Biocatalysis Group.

The Almac biocatalysis group has secured a prestigious BBSRC (Biotechnology and Biological Sciences Research Council) programme with UCL focused specifically on metagenomics and novel enzyme discovery. The R&D work concerned is set to be carried out jointly between Almac and the departments of Biochemical Engineering and Chemistry at UCL, with high level input from two world leaders in the field of biocatalyst discovery and application, Professors John Ward and Helen Hailes.

Dr. Tom Moody, Almac’s Head of Biocatalysis & Isotope Chemistry, commented “This clearly adds further depth to our expertise and complements our recent collaboration with DSM in accessing diverse enzyme collections.”

Professor Ward remarked: “We are very excited to continue working with Almac on this prestigious project, building on many years of collaboration and partnership. Indeed, this project will see our internal capabilities further developed with true industrial needs in our vision.”

The application of biocatalysis technology to the pharmaceutical and fine chemical industries is continuing to grow year on year and this trend is mirrored in the increasing number of synthetic projects being carried out by the biocatalysis group in Almac.

The only limitation of biocatalysis is in the number of diverse enzymes available in a given enzyme class, which dictates both the substrate range and the stereoselectivity observed for a desired chemical transformation. The majority of enzymes used in biocatalysis are derived from microbial sources. However, it is known that only a tiny percentage (as low as 0.1% from soil samples) of bacteria present in an environmental sample can be cultured and isolated.

Metagenomics, a culture-independent technique used to extract the total DNA from an environment, can circumvent this problem and allow access up to 99% of enzyme genes present in environmental samples. Work previously carried out at UCL has allowed a series of metagenomes to be obtained from various unusual sources. The use of bioinformatic tools developed by John Ward with Prof Christine Orengo of the Structural and Molecular Biology department at UCL will allow the metagenomes concerned to be mined for enzymes usable in both synthetic chemistry and synthetic biology projects.

Moody further commented “The need for more diverse enzymes has never been greater and this research programme further emphasises Almac’s commitment to UK research and to biocatalysis development.”

He continued; “The project will mainly focus on transaminase and cytochrome P450s enzymes. We will   identify, clone and express these enzymes before carrying out extensive screening against panels of ‘typical’ pharmaceutical and fine chemical substrates. This should enable us   to identify novel and commercially useful enzyme biocatalysts. As the follow-on step, directed evolution at Almac will enable further development of the lead enzymes concerned.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Drives Biocatalysis Leadership with a Further $7M Investment
The investment will help develop biocatalysts for scale-up chemistry.
Friday, February 20, 2015
Almac and ESMS Global Collaborate to Offer Unique Clinical Trial Support
Sponsors requesting 24/7 medical support & emergency unblinding can save time and money.
Friday, November 28, 2014
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Thursday, November 13, 2014
Almac Introduce Flexible Clinical Trial Direct to Patient Solution
Available for clinical studies conducted throughout the US & Canada.
Friday, October 31, 2014
Almac Expand its UK Commercial Packaging Facility
Company makes further significant co-investment to meet Japanese client demand for humidity controlled blister packaging.
Friday, October 10, 2014
Almac Forms Academia-Industry Collaboration
Collaboration aims to bring a novel chemical produced via an enzymatic route from under-utilised natural oil to the market.
Friday, September 19, 2014
Almac’s AADx Gene Expression Marker Attracts Significant Commercial Interest from Pharma
Evaluation in colorectal, breast and lung cancer to follow.
Thursday, June 26, 2014
Almac Profits Up 30%
Company will open a new clinical trial secondary packaging facility in Singapore.
Wednesday, May 28, 2014
Almac’s Diagnostics Business Unit Receives NY State Clinical Laboratory Permit
The Permit for trial enrichment and companion diagnostics development allows them to receive patient samples for clinical testing in New York.
Tuesday, April 15, 2014
Almac Achieves Double Success at Business Award Ceremony
Presented with both Excellence in Innovation & Technology.
Tuesday, April 01, 2014
Almac Expands Asia Pacific Operations
Comprehensive support for trials of any size or complexity whether they originate in Asia or include Asian sites.
Wednesday, March 12, 2014
Almac Wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
The awards held to recognize the success and achievements of Ireland’s internationally renowned scientists.
Thursday, December 12, 2013
Almac Announces Release of Enhanced 3PL Customer Billing Application
Company further enhance 3rd Party Logistics commercial support services for niche / orphan drugs.
Tuesday, November 19, 2013
Almac Increase Global Stability Storage Capacity
Company has completed a $2m investment programme.
Tuesday, November 05, 2013
Richard Segiel, Jr. Joins Almac as Vice President of US Business Development
Richard will focus on developing new business, maintaining existing business, and developing partnerships.
Wednesday, October 30, 2013
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos